Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Beyond administering CAR T-cell therapy and bispecifics, oncology nurses must apply proactive, supportive care and an understanding of complex treatments.

Transformative Care: A Nurse Guide to Novel Therapies in Blood Cancers

David A. Braun, MD, PhD, explained that personalized cancer vaccines can be associated with toxicities typical of both vaccines and immunotherapies.

Personalized Cancer Vaccines: Watching For Immune-Related, Vaccine AEs

Experts outline AE risks—including ICANS, CRS, HLH—as T-cell engager use expands, highlighting the crucial role of nurses and APPs.

Nurses, APPs Key to AE Management as T-Cell Engagers Move Into Solid Tumors

Hope S. Rugo, MD, FASCO, outlined the top considerations for nurses managing toxicities related to PI3K and AKT inhibitors in patients with breast cancer.

PI3K and AKT Inhibitor Toxicity Advice From a Breast Cancer Expert

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

From All Angles

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Ronald Bleday, MD, is the section chief of the Division of Colorectal Surgery and vice chair for quality and patient safety in the Department of Surgery at Brigham and Women’s Hospital in Boston, Massachusetts.

Articles

Bridget Hoyt is the assistant editor for Oncology Nursing News. She earned her BA in communication studies at Rider University with a minor in public relations. She can be reached at 

A significant reduction of opioid use in patients after colorectal surgery was supported by clinician and patient compliance, says Ronald Bleday, MD.

Opioid Reduction in Surgical Oncology Supported by Cultural Shift

Gina Mauro currently serves as Vice President of Content at MJH Life Sciences, overseeing 

®. Gina joined the company in 2015 and has held various positions on 

Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

A nurse-led clinic to aid in patient-reported symptom burden had high patient satisfaction.

How Can Nurses Provide Better Symptom Management for Patients With MPNs? 

Neurotoxicities can be monitored long term with personalized questions, according to Mary Steinbach, DNP, APRN.

Personalizing Neurotoxicity Monitoring After CAR T-Cell Therapy

Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

About Us

Editorial Board

Contact Us

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News – Clinical Insights for Cancer Care Nurses

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

View

The Advent of Oral Oncolytics and Patient Access

Multidisciplinary Approach to Managing Oral Oncolytics

Roles of the Oncologist Versus Pharmacist

The Efficacy and Safety of CDK4/6 Inhibitors

Practical Challenges in Switching to CDK4/6 Inhibitors

Medically Integrated Dispensing Service Best Practices

Oral Oncolytics and Patient Adherence

Medically Integrated Pharmacy Teams Spur Innovations

CDK4/6 Inhibitors in Metastatic Breast Cancer

Considerations for Treating Patients with CDK4/6 Inhibitors

Multidisciplinary Care in Breast Cancer

Best Practices for Managing Patients on CDK4/6 Inhibitors

Educating Patients and Staff on Using CDK4/6 Inhibitors

Improving Care for Patients With Metastatic Breast Cancer

Metastatic Breast Cancer: CDK4/6 Inhibitors

Benefits and Challenges of CDK4/6 Inhibitors

Patients' Perspectives on CDK4/6 Inhibitors

Multidisciplinary Approach: Managing CDK4/6 Inhibitors

Dispensing of CDK4/6 Inhibitors

Patient Management of CDK4/6 Inhibitors

Adherence With CDK 4/6 Inhibitors

Advances and Best Practices in the Utilization of Novel Agents in Metastatic Breast Cancer

Advances and Best Practices in the Utilization of Novel Agents in Metastatic Breast Cancer

Newsletter

Latest Conference Coverage